{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:38:41Z","timestamp":1792809521287,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40123-026-01504-z","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:20:50Z","timestamp":1790083250000},"page":"3709-3725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03622580","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03622593","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yiyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrek P.","family":"Hibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-8273","authenticated-orcid":false,"given":"Katie M.","family":"Litts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"4","key":"1504_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244\u201351.","journal-title":"Surv Ophthalmol"},{"key":"1504_CR2","doi-asserted-by":"publisher","first-page":"2156273","DOI":"10.1155\/2016\/2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res. 2016;2016:2156273.","journal-title":"J Diabetes Res"},{"issue":"6","key":"1504_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.oret.2023.01.018","volume":"7","author":"K Sarici","year":"2023","unstructured":"Sarici K, Yordi S, Martin A, et al. Longitudinal quantitative ultrawide-field fluorescein angiography dynamics in the RUBY diabetic macular edema study. Ophthalmol Retina. 2023;7(6):543\u201352.","journal-title":"Ophthalmol Retina"},{"key":"1504_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-4-27","volume":"4","author":"X Zhang","year":"2014","unstructured":"Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.","journal-title":"Cell Biosci"},{"issue":"4","key":"1504_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331\u201371.","journal-title":"Prog Retin Eye Res"},{"key":"1504_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/632307","volume":"2014","author":"FR Stefanini","year":"2014","unstructured":"Stefanini FR, Badar\u00f3 E, Falabella P, Koss M, Farah ME, Maia M. Anti-VEGF for the management of diabetic macular edema. J Immunol Res. 2014;2014:632307.","journal-title":"J Immunol Res"},{"issue":"6","key":"1504_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond). 2018;32(6):1010\u201320.","journal-title":"Eye (Lond)"},{"issue":"12","key":"1504_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/eye.2016.174","volume":"30","author":"M Ashraf","year":"2016","unstructured":"Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye (Lond). 2016;30(12):1531\u201341.","journal-title":"Eye (Lond)"},{"issue":"4","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jcjo.2022.03.003","volume":"58","author":"A Kalur","year":"2023","unstructured":"Kalur A, Iyer AI, Muste JC, Talcott KE, Singh RP. Impact of retinal fluid in patients with diabetic macular edema treated with anti-VEGF in routine clinical practice. Can J Ophthalmol. 2023;58(4):271\u20137.","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"1504_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","volume":"34","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Campbell J, Dugel PU, et al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data. Eye (Lond). 2020;34(3):480\u201390.","journal-title":"Eye (Lond)"},{"issue":"1","key":"1504_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41433-023-02637-2","volume":"38","author":"R Khoramnia","year":"2024","unstructured":"Khoramnia R, Nguyen QD, Kertes PJ, et al. Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema. Eye (Lond). 2024;38(1):54\u201360.","journal-title":"Eye (Lond)"},{"issue":"8","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase\u00a02 randomized trial. Ophthalmology. 2019;126(8):1155\u201370.","journal-title":"Ophthalmology"},{"issue":"11","key":"1504_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","journal-title":"EMBO Mol Med"},{"issue":"10326","key":"1504_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16\u00a0weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase\u00a03 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1504_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase\u00a03 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"key":"1504_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","volume":"232","author":"MR Starr","year":"2021","unstructured":"Starr MR, Salabati M, Mahmoudzadeh R, et al. Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting. Am J Ophthalmol. 2021;232:90\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1504_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100972","volume":"86","author":"U Schmidt-Erfurth","year":"2022","unstructured":"Schmidt-Erfurth U, Reiter GS, Riedl S, et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Prog Retin Eye Res. 2022;86:100972.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"1504_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00417-019-04592-9","volume":"258","author":"JF Korobelnik","year":"2020","unstructured":"Korobelnik JF, Daien V, Faure C, et al. Real-world outcomes following 12\u00a0months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):521\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"1504_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamaophthalmol.2020.2457","volume":"138","author":"PK Roberts","year":"2020","unstructured":"Roberts PK, Vogl WD, Gerendas BS, et al. Quantification of fluid resolution and visual acuity gain in patients with diabetic macular edema using deep learning: a post hoc analysis of a randomized clinical trial. JAMA Ophthalmol. 2020;138(9):945\u201353.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/IAE.0000000000002110","volume":"39","author":"PU Dugel","year":"2019","unstructured":"Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88\u201397.","journal-title":"Retina"},{"issue":"4","key":"1504_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185\u2013222.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1504_CR22","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern\u00ae. Ophthalmology. 2020;127(1):P66\u2013145.","journal-title":"Ophthalmology"},{"issue":"10","key":"1504_CR23","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125(10):1608\u201322.","journal-title":"Ophthalmology"},{"issue":"2\u20133","key":"1504_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000481711","volume":"239","author":"Y Koyanagi","year":"2018","unstructured":"Koyanagi Y, Yoshida S, Kobayashi Y, et al. Visual outcomes based on early response to anti-vascular endothelial growth factor treatment for diabetic macular edema. Ophthalmologica. 2018;239(2\u20133):94\u2013102.","journal-title":"Ophthalmologica"},{"key":"1504_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/OPTH.S285388","volume":"15","author":"S Dabir","year":"2021","unstructured":"Dabir S, Rajan M, Parasseril L, et al. Early visual functional outcomes and morphological responses to anti-vascular growth factor therapy in diabetic macular oedema using optical coherence tomography angiography. Clin Ophthalmol. 2021;15:331\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"1504_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13101735","volume":"13","author":"S Chouhan","year":"2023","unstructured":"Chouhan S, Kalluri Bharat RP, Surya J, et al. Preliminary report on optical coherence tomography angiography biomarkers in non-responders and responders to intravitreal anti-VEGF injection for diabetic macular oedema. Diagnostics (Basel). 2023;13(10):1735.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"1504_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/2474126416682569","volume":"1","author":"AR Shah","year":"2017","unstructured":"Shah AR, Yonekawa Y, Todorich B, et al. Prediction of anti-VEGF response in diabetic macular edema after 1 injection. J Vitreoretin Dis. 2017;1(3):169\u201374.","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"1504_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2022","unstructured":"Eter N, Singh RP, Abreu F, et al. YOSEMITE and RHINE: phase\u00a03 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci. 2022;2(1):100111.","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"1504_CR29","first-page":"2406","volume":"65","author":"S Pla Alemany","year":"2024","unstructured":"Pla Alemany S, Albrecht T, Valcarcel A, et al. Deep learning-based optical coherence tomography segmentation of retinal fluids and layers using multi-grader annotations. Invest Ophthalmol Vis Sci. 2024;65(7):2406.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1504_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1109\/TMI.2004.828354","volume":"23","author":"SK Warfield","year":"2004","unstructured":"Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation. IEEE Trans Med Imaging. 2004;23(7):903\u201321.","journal-title":"IEEE Trans Med Imaging"},{"issue":"8","key":"1504_CR31","first-page":"578","volume":"66","author":"T Albrecht","year":"2025","unstructured":"Albrecht T, Hibar D, Chen M, Chang V, Ferrara D, Lu H. Repeatability study for retinal optical coherence tomography (OCT) segmentation algorithms (ROSA) in neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Vis Sci. 2025;66(8):578.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1504_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.oret.2025.01.017","volume":"9","author":"JI Lim","year":"2025","unstructured":"Lim JI, Amador MJ, Dhoot DS, et al. Anatomic control with faricimab versus aflibercept in the YOSEMITE\/RHINE trials in diabetic macular edema. Ophthalmol Retina. 2025;9(7):655\u201366.","journal-title":"Ophthalmol Retina"},{"key":"1504_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ajo.2020.11.010","volume":"224","author":"JP Ehlers","year":"2021","unstructured":"Ehlers JP, Uchida A, Sevgi DD, et al. Retinal fluid volatility associated with interval tolerance and visual outcomes in diabetic macular edema in the VISTA phase\u00a0III trial. Am J Ophthalmol. 2021;224:217\u201327.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1504_CR34","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045\u201353.","journal-title":"Ophthalmology"},{"issue":"2","key":"1504_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bjophthalmol-2017-310483","volume":"102","author":"BS Gerendas","year":"2018","unstructured":"Gerendas BS, Prager S, Deak G, et al. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Br J Ophthalmol. 2018;102(2):195\u2013203.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1504_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.oret.2024.11.015","volume":"9","author":"RA Goldberg","year":"2025","unstructured":"Goldberg RA, Mar FA, Csaky K, et al. Resolution of angiographic macular leakage with faricimab versus aflibercept in patients with diabetic macular edema in YOSEMITE\/RHINE. Ophthalmol Retina. 2025;9(6):515\u201326.","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"1504_CR37","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.5.26","volume":"65","author":"EL von Schulthess","year":"2024","unstructured":"von Schulthess EL, Maunz A, Chakravarthy U, et al. Intraretinal hyper-reflective foci are almost universally present and co-localize with intraretinal fluid in diabetic macular edema. Invest Ophthalmol Vis Sci. 2024;65(5):26.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1504_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajo.2021.10.017","volume":"236","author":"C Jhaveri","year":"2022","unstructured":"Jhaveri C, Wykoff CC, Khanani AM, et al. Early residual fluid-free status and long-term BCVA outcomes: a treatment agnostic, post hoc analysis of pooled HAWK and HARRIER data. Am J Ophthalmol. 2022;236:12\u20139.","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01504-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01504-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01504-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:04:34Z","timestamp":1792807474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01504-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01504-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yiyi Wang, Derrek P. Hibar, Andreas Maunz, Huanxiang Lu, Manuel Amador, and Katie M. Litts are employees of Genentech, Inc. Srinivas Sadda has been a consultant (honorarium) for 4DMT, Alexion, Alkeus, Allergan\/AbbVie, Alnylam, Amgen, Apellis, Arrowhead, Astellas, Biogen, Boehringer Ingelheim, Heidelberg Engineering, iCare, Nanoscope, Neurotech, Notal, Novartis, ONL Therapeutics, Optos, Oxurion, Pfizer, Regeneron, Roche\/Genentech, Inc., Samsung Bioepis, Surrozen, and Topcon; has received research instruments from Heidelberg Engineering, iCare, Intalight, Nidek, Optos, Topcon, and ZEISS; has been a symposium speaker (honorarium) from Heidelberg Engineering, Nidek, Novartis Pharma AG, Roche, Topcon, and ZEISS; and has received financial support from Heidelberg Engineering, iCare\/Centervue, Intalight, Nidek, Optos, Topcon, and ZEISS. Jennifer I. Lim has been on advisory boards for Alimera, Regeneron, and Regenxbio; has been a consultant for Allergan, Aura, Boehringer Ingelheim, Cognition, Eyenuk, EyePoint, Iveric Bio, Luxa, Novartis Pharma AG, Opthea, Quark, Regeneron, RetinAI, Roche\/Genentech, Inc., Santen, Unity, and Viridian; and has received grant support from Adverum, Aldeyra, Astellas, Chengdu Kanghong, Graybug, Kyoyo Drug Development, NGM Bio, Regeneron, Regenxbio, Roche\/Genentech, Inc., Spring Vision, and Stealth. Clement K. Chan has received grant support from Bayer, Genentech, Inc., Iveric Bio, Juvenile Diabetes Research Foundation, National Eye Institute, NIDDK, Opthea, and Retinal Patch Technologies; and is a stockholder of Unifeye Vision Partners. Gavin S. Tan has been a consultant for AbbVie\/Allergan, Bayer, Novartis, and Roche. Katherine E. Talcott has been a consultant for Alimera, Allergan, Apellis, Bausch\u2009+\u2009Lomb, EyePoint, Genentech, Inc., Outlook, Regeneron, and ZEISS; has done research for Regeneron and ZEISS; and has been on the speakers bureau for Genentech, Inc., Iveric Bio, and ZEISS. Kara Gibson is an employee of Roche Products Ltd. and has stock options in Roche Products Ltd. Andreas Maunz, Huanxiang Lu, and Thomas Albrecht are employees of F. Hoffmann-La Roche Ltd.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YOSEMITE and RHINE were conducted in accordance with the International Council for Harmonization E6 Guideline for Good Clinical Practice, tenets of the Declaration of Helsinki, US Food and Drug Administration regulations, and the European Union Clinical Trials Directive (2001\/20\/EC) as appropriate; and all applicable local, state, and federal laws. The YOSEMITE\/RHINE study protocols were approved by applicable institutional review boards and ethics committees before trial commencement. All patients provided written informed consent to participate.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}